Clinical Trial Update: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment [Phase 2]

View source ↗

Summary

Phase II trial of Ertumaxomab for metastatic or advanced breast cancer that progressed after endocrine therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ertumaxomab (ertumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: TERMINATED